Magnitude Biosciences Celebrates Seven Years at the Heart of NETPark

Magnitude Biosciences Marks Seven Years at the heart of NETPark

From an academic idea to a thriving high-growth biotech company, Magnitude Biosciences Ltd is celebrating seven years of scientific innovation and commercial success.

A spin-out from Durham University, Magnitude was founded in 2018 with a clear mission: to revolutionise how researchers study ageing, toxicity, and drug efficacy using C. elegans, a tiny but powerful model organism. Since then, the company has grown into a leading contract research organisation (CRO), employing over 20 team members and supporting partners across the biotech, pharmaceutical, nutraceutical and cosmeceutical sectors.

The science park provides a conducive environment and a collaborative ecosystem that fosters innovation,” said Dr Fozia Saleem, CEO of Magnitude Biosciences.

Based at NETPark in Sedgefield, Magnitude has benefited from an ecosystem designed to support science-led businesses — offering specialist facilities, access to expertise, and a community of like-minded innovators.

The company’s unique research platform uses C. elegans to provide rapid, ethical, and cost-effective insights into compound effects — supporting early-stage drug discovery, target validation, longevity research, and toxicity screening.

Now seven years in, Magnitude continues to scale, both in its scientific capabilities and its global impact. The company remains committed to pushing the boundaries of preclinical research — and doing so from its home at NETPark.

NETPark congratulates the entire Magnitude team on this exciting milestone and looks forward to supporting their continued growth in the years to come.